1. Scrip
  2. >>Business
  3. >>Legal & IP

Allergan's Tribe Deal Over Restasis Sparks Ire From Legislators

 
• By Jessica Merrill

Pharmaceutical manufacturers have been hoping to fly under Washington, D.C.'s radar, but Allergan's attempt to shield Restasis from the IPR process using a controversial deal with a Native American tribe, has led to calls for an investigation.

The fight over the Affordable Care Act and the repeal and replace of Obamacare concept.In American politics US parties are represented by either the democrat donkey or republican elephant

Allergan PLC's pact with the Saint Regis Mohawk Tribe, intended to help Allergan secure patent protection for its dry eye blockbuster Restasis (cyclosporine), has done what many companies are hoping not to do – caught the attention of legislators in Washington, D.C.

Four Democratic Senators sent a letter to Senate Judiciary Committee Chairman Charles Grassley, R-IA, Sept. 27 calling on the committee...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Business

Saudi Arabia Plans Advanced Manufacturing Campus Under Biotech Drive

 
• By Aakash Babu

A partnership with Germfree Laboratories will bring a new facility to boost Saudi Arabia’s biotech sector as the world’s largest oil exporter tries to establish itself as a global biotech hub by 2040.

Bitcoin Player Parataxis To Acquire Bridge Biotherapeutics After IPF Failure

 
• By Jung Won Shin

After the failure of its lead asset in a Phase II trial earlier this year, Korea's Bridge Biotherapeutics has accepted an acquisition offer from bitcoin group Parataxis.

Cidara’s Fortunes Improve Quickly With Non-Vaccine Flu-Prevention Data

 
• By Joseph Haas

Having recently abandoned the antifungal space, Cidara’s stock soared on Phase IIb data showing that its drug-Fc conjugate prevents seasonal flu at rates from 57%-76%.